Chemotherapy agents are notorious for producing severe side-effects. To overcome the challenge of this off-target toxicity, many approaches have been developed to selectively delivery chemotherapy directly to the tumor. One such approach is transarterial chemoembolization (TACE), in which chemotherapy is introduced via catheter directly into the tumor vasculature. Despite this site-specific delivery, however, about half of the chemotherapy dose passes through the tumor, enters systemic circulation, and causes off-target damage. To address this problem, we are developing materials that are capable of capturing this residual chemotherapy from the bloodstream. Ultimately, these materials will be used to construct a device (a "chemofilter") that can be depolyed via catheter "downstream" from the tumor, enabling excess chemotherapy to be intercepted and sequestered before entering systemic circulation. Our approach involves the attachment of drug-capture materials to potential device surfaces. One such drug-capture material is genomic DNA, which enables the capture of DNA-targeting chemotherapy agents. We have explored several methods of achieving DNA attachment to a variety of surfaces, and have investigated the ability of different materials to remove chemotherapy agents from biologically relevant solutions, including human serum and porcine blood. We have observed effective drug capture from solution at clinically relevant concentrations and timescales, indicating that drug capture is a viable strategy for mitigating the harmful side-effects associated with chemotherapy.

Materials for drug capture: An approach to mitigating the off-target toxicity of chemotherapy

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.